☆ 4.7 Article

Structure-based identification of new orally bioavailable BRD9-PROTACs for treating acute myelocytic leukemia

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Editorial Material Hematology

Acute myeloid leukemia: introduction to a series highlighting progress and ongoing challenges

Richard F. Schlenk

HAEMATOLOGICA (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

Design of Class I/IV Bromodomain-Targeting Degraders for Chromatin Remodeling Complexes

Huda Zahid et al.

Summary: Targeted protein degradation is an emerging technology that can modulate the activity of epigenetic proteins. In this study, degraders for bromodomain-containing proteins were designed based on two scaffolds derived from pyridazinone and pyrimidine-based heterocycles. These heterobifunctional molecules were found to be cell-permeable, capable of forming ternary complexes, and able to degrade specific proteins. The results highlight the potential of targeted protein degradation for therapeutic applications.

ACS CHEMICAL BIOLOGY (2023)

添加到收藏夹

Review Biochemistry & Molecular Biology

Epigenetic modulation by targeting bromodomain containing protein 9 (BRD9): Its therapeutic potential and selective inhibition

Maria Mushtaq Ali et al.

Summary: BRD9 inhibitors have potential therapeutic value in cancer treatment by selectively targeting BRD9 and BRD7 proteins, regulating chromatin structure and gene expression, and inhibiting tumor growth and progression.

INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2023)

添加到收藏夹

Review Oncology

Recent advances in targeted therapies in acute myeloid leukemia

Rahul S. S. Bhansali et al.

Summary: Acute myeloid leukemia (AML), the most common acute leukemia in adults, has seen significant advancements in understanding its molecular profile and treatment options in the past decade. The classification of AML subtypes has shifted from morphology to molecular and genetic basis, leading to improved outcomes with low-intensity induction therapy and targeted oral therapies. However, challenges remain in sequencing and combining therapies, as well as addressing poor prognosis in certain subtypes like TP53 mutations. This review discusses recent updates in AML classification, low-intensity and novel oral combination therapies, and ongoing translational advances for high-risk disease subtypes.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2023)

添加到收藏夹

Article Medicine, General & Internal

Acute myeloid leukaemia

Courtney D. Dinardo et al.

Summary: Progress in acute myeloid leukaemia treatment has seen significant improvements in scientific understanding, prognostication tools, risk assessments, and incorporation of measurable residual disease into risk assessments. Recent updates in classification and recommendations by organizations such as WHO, ICC, and European LeukemiaNet have provided enhanced guidance for prognostic stratification and treatment response assessment. There have also been advancements in treatment options, leading to improved outcomes for both newly diagnosed and relapsed patients.

LANCET (2023)

添加到收藏夹

Review Biochemistry & Molecular Biology

PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies

Nuwayo Ishimwe Sincere et al.

Summary: Targeted protein breakdown using PROTACs technology is a potential therapeutic strategy for conditions caused by abnormal protein production. PROTACs utilize an event-driven pharmacology to inhibit protein function and trigger its degradation. The development of potent, tissue- and cell-specific PROTAC compounds remains a challenge.

MOLECULES (2023)

添加到收藏夹

Article Chemistry, Medicinal

Structural Feature Analyzation Strategies toward Discovery of Orally Bioavailable PROTACs of Bruton's Tyrosine Kinase for the Treatment of Lymphoma

Jingyu Zhang et al.

Summary: In this study, dimensionality reduction analysis and model molecule validation were used to identify key structural features for improving the oral absorption of BTK-PROTACs. The newly discovered BTK-PROTACs B1 and B2 were optimized based on the results. Compound C13 with improved oral bioavailability, high BTK degradation activity, and selectivity was discovered. It showed inhibitory effects against hematologic cancer cells and attenuated the BTK-related signaling pathway. The oral administration of C13 effectively reduced BTK protein levels and suppressed tumor growth. This study led to the discovery of a new orally bioavailable BTKPROTAC for the treatment of lymphoma.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

添加到收藏夹

Article Oncology

BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma

Ellen Weisberg et al.

Summary: BRD9 has been identified as a critical therapeutic target in acute leukemias and multiple myeloma. Depletion of BRD9 protein induces terminal differentiation in AML cells and apoptosis in ALL and MM cells. RNA-seq analysis reveals the impact of BRD9 degradation on various signaling pathways, including those related to inflammation, cell adhesion, DNA repair, and cell cycle progression. Degradation of BRD9 enhances the efficacy of chemotherapy and targeted therapies in AML, ALL, and MM. Therefore, further development of therapeutic strategies targeting BRD9 is of great importance.

BLOOD CANCER JOURNAL (2022)

添加到收藏夹

Article Medicine, Research & Experimental

The Role of Somatic Mutations in Acute Myeloid Leukemia Pathogenesis

Ashwin Kishtagari et al.

Summary: AML is characterized by genetic and epigenetic aberrations, with mutations acquired stepwise. Understanding the pathogenesis of AML informs the development of prognostic models and therapeutic strategies.

COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2021)

添加到收藏夹

Article Chemistry, Multidisciplinary

Phenyl-Glutarimides: Alternative Cereblon Binders for the Design of PROTACs

Jaeki Min et al.

Summary: IMiDs and IMiD-based PROTACs rapidly hydrolyze in commonly utilized cell media, affecting their efficacy; Novel CRBN binders, phenyl glutarimide (PG) analogues, were designed with high affinity and improved stability; Discovery of PG PROTAC 4c as a potent degrader of BET proteins, supporting the utility of PG derivatives in CRBN-directed PROTACs design.

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2021)

添加到收藏夹

Review Hematology

A review of FDA-approved acute myeloid leukemia therapies beyond '7+3'

Alexandre Bazinet et al.

Summary: The treatment paradigm for AML is rapidly evolving, with promising new drugs targeting driver mutations improving outcomes in specific AML subgroups, and advances in low-intensity therapies providing meaningful disease control for patients unfit for standard induction chemotherapy. Ongoing work focuses on identifying synergistic drug combinations and optimal treatment selection guided by individual patient and disease features.

EXPERT REVIEW OF HEMATOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers

Eric J. Duncavage et al.

Summary: This study showed that whole-genome sequencing provided rapid and accurate genomic profiling in patients with AML or MDS, with a greater diagnostic yield than conventional cytogenetic analysis, and more efficient risk stratification based on standard risk categories.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Oncology

The BRD9/7 Inhibitor TP-472 Blocks Melanoma Tumor Growth by Suppressing ECM-Mediated Oncogenic Signaling and Inducing Apoptosis

Lawrence David Mason et al.

Summary: Melanoma is a deadly form of skin cancer with limited treatment options. This study identified TP-472 as a potential effective therapeutic agent for melanoma by blocking cancer-promoting signaling pathways and inducing cell death. Further research is needed to explore the full potential of TP-472 in melanoma therapy.

CANCERS (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation

Michael J. Bond et al.

Summary: The discovery of PROTACs has revolutionized targeted protein degradation, leading to the development of orally bioavailable clinical drugs. Future advancements in technology will expedite the discovery of new degraders and E3 ligases, as well as the identification of active degraders.

RSC CHEMICAL BIOLOGY (2021)

添加到收藏夹

Article Oncology

Targeting BRD9 by I-BRD9 efficiently inhibits growth of acute myeloid leukemia cells

Lixin Zhou et al.

Summary: The BRD9 inhibitor I-BRD9 shows significant growth inhibitory effects on AML cells, likely through inducing apoptosis and inhibiting the cell cycle. This suggests that BRD9 may play a crucial role in AML cells, and I-BRD9 could be a potential therapeutic agent for AML treatment.

TRANSLATIONAL CANCER RESEARCH (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

Fundamental aspects of DMPK optimization of targeted protein degraders

Carina Cantrill et al.

DRUG DISCOVERY TODAY (2020)

添加到收藏夹

Article Multidisciplinary Sciences

The bromodomain containing protein BRD-9 orchestrates RAD51-RAD54 complex formation and regulates homologous recombination-mediated repair

Qin Zhou et al.

NATURE COMMUNICATIONS (2020)

添加到收藏夹

Article Chemistry, Medicinal

Improved Accuracy for Modeling PROTAC-Mediated Ternary Complex Formation and Targeted Protein Degradation via New In Silico Methodologies

Michael L. Drummond et al.

JOURNAL OF CHEMICAL INFORMATION AND MODELING (2020)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Targeting BRD9 for Cancer Treatment: A New Strategy

Xiuzuo Zhu et al.

ONCOTARGETS AND THERAPY (2020)

添加到收藏夹

Article Chemistry, Medicinal

In Silico Modeling of PROTAC-Mediated Ternary Complexes: Validation and Application

Michael L. Drummond et al.

JOURNAL OF CHEMICAL INFORMATION AND MODELING (2019)

添加到收藏夹

Article Cell Biology

BRD9 binds cell type-specific chromatin regions regulating leukemic cell survival via STAT5 inhibition

Nunzio Del Gaudio et al.

CELL DEATH & DISEASE (2019)

添加到收藏夹

Article Multidisciplinary Sciences

BRD9 defines a SWI/SNF sub-complex and constitutes a specific vulnerability in malignant rhabdoid tumors

Xiaofeng Wang et al.

NATURE COMMUNICATIONS (2019)

添加到收藏夹

Review Chemistry, Medicinal

Proteolysis targeting chimeras (PROTACs) in 'beyond rule-of-five' chemical space: Recent progress and future challenges

Scott D. Edmondson et al.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)

添加到收藏夹

Meeting Abstract Hematology

Superior Pre-Clinical Efficacy of Novel Protac Based BET Degrader in a Large Acute Myeloid Leukemia Cohort

Malathi Kandarpa et al.

BLOOD (2019)

添加到收藏夹

Review Oncology

HDAC Inhibitors in Acute Myeloid Leukemia

Edurne San Jose-Eneriz et al.

CANCERS (2019)

添加到收藏夹

Article Chemistry, Medicinal

Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel-Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7

Vittoria Zoppi et al.

JOURNAL OF MEDICINAL CHEMISTRY (2019)

添加到收藏夹

Article Biology

Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma

Gerard L. Brien et al.

ELIFE (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

BRD9 Inhibition, Alone or in Combination with Cytostatic Compounds as a Therapeutic Approach in Rhabdoid Tumors

Katja F. Kraemer et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)

添加到收藏夹

Article Chemistry, Medicinal

Inhibition of bromodomain-containing protein 9 for the prevention of epigenetically-defined drug resistance

Terry D. Crawford et al.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)

添加到收藏夹

Article Chemistry, Multidisciplinary

Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands

David Remillard et al.

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2017)

添加到收藏夹

Review Hematology

Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia

Bas J. Wouters et al.

BLOOD (2016)

添加到收藏夹

Article Chemistry, Medicinal

Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition

Natalie H. Theodoulou et al.

JOURNAL OF MEDICINAL CHEMISTRY (2016)

添加到收藏夹

Article Oncology

Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia

Ngai Cheung et al.

CANCER CELL (2016)

添加到收藏夹

Article Chemistry, Medicinal

Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor

Laetitia J. Martin et al.

JOURNAL OF MEDICINAL CHEMISTRY (2016)

添加到收藏夹

Article Biochemistry & Molecular Biology

Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition

Anja F. Hohmann et al.

NATURE CHEMICAL BIOLOGY (2016)

添加到收藏夹

Article Chemistry, Multidisciplinary

LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor

Peter G. K. Clark et al.

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2015)

添加到收藏夹

Review Medicine, General & Internal

Acute Myeloid Leukemia

Hartmut Doehner et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Oncology

The NCI60 human tumour cell line anticancer drug screen

Robert H. Shoemaker

NATURE REVIEWS CANCER (2006)

添加到收藏夹

Article Biochemistry & Molecular Biology

Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells

A Nebbioso et al.

NATURE MEDICINE (2005)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.